Healios K.K.

Healios K.K. is a leading Japanese clinical-stage biotechnology company specializing in regenerative medicine and cell therapy. Founded in 2011 by Dr. Tadahisa Kagimoto, the company is a pioneer in the development of therapies utilizing both somatic stem cells and induced pluripotent stem cells (iPSCs). Healios focuses on high unmet medical needs in critical care, neurology, and oncology, with a mission to provide innovative treatments for life-threatening conditions such as acute respiratory distress syndrome (ARDS), ischemic stroke, and solid tumors. The company operates through two primary technology platforms: a somatic stem cell platform based on its lead product HLCM051 (invimestrocel), and an iPSC platform focused on engineered natural killer (eNK) cells and universal donor cells (UDC). In 2024, Healios significantly expanded its global footprint and intellectual property portfolio by acquiring substantially all assets from its former partner Athersys, including the MultiStem technology and over 400 related patents. This acquisition allows Healios to lead the global development and commercialization of its core pipeline assets independently.